The Supreme Court is weighing the legality of Trump's executive order that looks to end birthright citizenship and "birth tourism," which the administration argues “rewards illegal immigration."
Mohammad Sharifullah is on trial for his alleged role in the Abbey Gate massacre. A judge will now need to rule if the trial will continue.
Hard-line regime figures seem to be calling the shots in Tehran, complicating U.S. efforts to negotiate an end to the conflict.
The Houston Police Department will comply with an amended order passed by the Houston City Council related to immigration enforcement.
A federal appeals court ruling upholding a Texas law requiring Ten Commandments displays in public school classrooms is setting up a potential challenge before the U.S. Supreme Court over the role of religion in public education.
Michigan Sec. of State and Democrat gubernatorial candidate Jocelyn Benson is facing scrutiny over her past role with the SPLC following the group's federal indictment. Benson served on the SPLC’s board of directors from 2014 through early 2019.
Officials are investigating whether Chris Nanos misrepresented his work history when he applied for a position in Pima County.
President Trump on Thursday announced a drug pricing deal with Regeneron — the last of 17 manufacturers the administration pressured last year to commit to his "most favored nation" policy. Why it matters: The deals with the other companies to lower certain drug prices are being touted as one of the administration's signature health accomplishments, though Democrats question whether the confidential arrangements are really helping consumers. Driving the news: Like other deals, the agreement calls for lower prices for certain drugs offered to Medicaid, as well as to patients paying cash through the TrumpRx website. - Trump claimed the deal amounts to "the biggest cut in drug prices in the history of our country, by many percentage…
Warner Bros. Discovery shareholders on Thursday voted "overwhelmingly" in favor of the merger with Paramount Skydance, clearing a critical hurdle. - Yes, but: Shareholders did not approve the executive compensation package presented at the meeting. Why it matters: The executive compensation package would have seen CEO David Zaslav earning at least $500 million. Zoom in: More than 1.4 billion votes were cast against the compensation proposal, versus the 307.7 million in favor. Each share of WBD common stock is entitled to one vote. - The compensation proposal was an advisory, non-binding vote and not a condition for completion of the deal. - The executives could still earn the payments outlined in the package if the deal closes,…
The newspaper’s ombudsman, Jacqueline Smith, said she had been given no reason for her dismissal.